Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope

Area of Science:

• Gene Therapy
• Retroviral Vectors
• Molecular Biology

Background:

• Gibbon Ape Leukemia Virus envelope protein (GALV-Env) is crucial for gene therapy due to its efficient transduction of human lymphocytes.
• Chimeric GALV-Env proteins, like GALV-C4070A, are used for pseudotyping lentiviral vectors.
• Improving expression efficiency and vector titers is essential for advanced gene therapy applications.

Purpose of the Study:

• To develop a codon-optimized (co) variant of the chimeric GALV-C4070A envelope protein (coGALV-Env) to enhance vector production.
• To evaluate the pseudotyping efficiency of coGALV-Env with different retroviral and lentiviral vectors.
• To assess the transduction efficiency of coGALV-Env-pseudotyped vectors on primary human T cells.

Main Methods:

• Construction and expression of a codon-optimized GALV-C4070A variant (coGALV-Env).
• Pseudotyping of γ-retroviral, α-retroviral, and lentiviral vectors using coGALV-Env.
• Titration of vector preparations on HEK293T cells and assessment of transduction efficiency on primary human T cells.

Main Results:

• coGALV-Env efficiently pseudotyped γ-retroviral, α-retroviral, and lentiviral vectors.
• Vector titers achieved with coGALV-Env were comparable to classical GALV-Env.
• Significantly lower plasmid amounts (20 ng/10^6 cells) were required for coGALV-Env transient production.
• coGALV-Env-pseudotyped vectors demonstrated efficient transduction of primary human T cells.

Conclusions:

• The novel chimeric coGALV-Env gene is highly effective for producing high-titer vector preparations.
• coGALV-Env facilitates efficient gene transfer into primary human T cells, suitable for CAR or TCR therapies.
• The reduced plasmid requirement offers a significant cost advantage for Good Manufacturing Practice (GMP) vector production.